• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Society for Biomaterials annual meeting and exposition >Enzyme Retention via Galectin-3 for In Vivo Administration of Therapeutics
【24h】

Enzyme Retention via Galectin-3 for In Vivo Administration of Therapeutics

机译：通过Galectin-3进行体内药物治疗的酶保留

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In this study, we have established Gal3 as a platform for the retention of protein based therapy. We have demonstrated that Gal3 is a viable platform the for localization of enzymes, especially in the subQ space, for up to 7 days. Differences in results among subQ injection sites may be due to variability in relative volume of these spaces. For example, the subQ space of the scruff versus the hock. Larger volume may result in more diffuse distribution of the fusion protein, and less interaction with furimazine. Overall, the NanoLuc-Gal3 remains in situ longer than enzyme alone. These results demonstrate the ability of Gal3 to bind to the ECM, and are promising for Gal3 as a platform retention method for protein based therapies.
机译：在这项研究中，我们已经建立了Gal3作为保留基于蛋白质的疗法的平台。我们已经证明，Gal3是一个可行的平台，可用于长达7天的酶定位，尤其是在subQ空间中。 subQ注入位点之间结果的差异可能是由于这些空间的相对体积变化所致。例如，头皮的subQ空间与飞节的空间有关。较大的体积可能导致融合蛋白的扩散分布更多，而与呋喃嗪的相互作用则减少。总体而言，NanoLuc-Gal3的原位保留时间比单独的酶长。这些结果证明了Gal3与ECM结合的能力，并有望将Gal3作为基于蛋白质的疗法的平台保留方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号